Cardiovascular Risk Management and Hepatitis C: Combining Drugs
نویسندگان
چکیده
منابع مشابه
Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management
Clinical guidelines now recognize the importance of a multifactorial approach to managing cardiovascular (CV) risk. This idea was taken a step further with the concept of the Polypill™. There are, however, considerable patent, pharmacokinetic, pharmacodynamic, registration, and cost implications that will need to be overcome before the Polypill™ or other single-pill combinations of CV medicatio...
متن کاملHepatitis C new drugs
Hepatitis C virus infection remains a significant global health problem with more than 130 Million individuals being chronically infected world-wide. Since 2001, the standard therapy of chronic hepatitis has been PEGIFNa + ribavirin. A large number of new direct acting antiviral agents is currently explored in clinical trials. Different viral proteins are targeted by these novel agents. The fir...
متن کاملADHD drugs and cardiovascular risk.
1445 box” warning describing the cardiovascular risks of stimulant drugs used to treat attention deficit–hyperactivity disorder (ADHD). This action was unexpected, largely because the FDA had not requested a review of current labeling for this class of drugs; it had merely asked for recommendations of approaches to studying the cardiovascular risks associated with these drugs. The committee, ho...
متن کاملChronic hepatitis C virus infection, a new cardiovascular risk factor?
Among the large scope of extrahepatic manifestations related to hepatitis C virus (HCV) infection, many studies recently evaluated the frequency and characteristics of cardiovascular involvement. To assess the current published data on HCV infection and cardiovascular diseases. Published studies on cardiovascular disease, i.e. cerebrovascular accident and ischaemic heart disease in subjects wit...
متن کاملModeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis.
Hepatitis C virus (HCV) infection can be cured by standard pegylated interferon (IFN) + ribavirin drug therapy in 30-50% of treatment-naïve genotype 1 HCV patients. Cure rate is defined as a sustained viral response measured 6 months after the end of treatment. Recently, Fujiwara et al. [Hepatol Res 2007;37:701-710], using a double-filtration plasmapheresis (DFPP) technique, showed that simple ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Pharmacokinetics
سال: 2018
ISSN: 0312-5963,1179-1926
DOI: 10.1007/s40262-018-0710-1